Eli Lilly Is Not Replacing Zepbound – Building an Obesity Empire

Eli Lilly’s continued success with Zepbound reinforces its leadership in the obesity market, a positive signal for investors. However, the stock price is trading below both the 20‑day and 50‑day moving averages, creating short‑term resistance. With an RSI of 46.8 and the MACD remaining below its signal line, the current trend still appears weak. Consequently, while the news is favorable, market reaction may be limited. Analysts expect a modest short‑term rebound in price, but a significant move is not anticipated in the near term.